Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 7/20 | 0.82 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
| ▸ | MARS1 | P56192 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 2/20 | 0.38 |
| ▸ | CTSA | P10619 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | TSPO | P30536 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9894206 | 0.95 | MDM2 (0.83) | MDM2PIN1MARS1ATMKMO | |
| SCHEMBL9893692 | 0.92 | MDM2 (0.68) | MDM2MARS1KMOHTTGABRA2 | |
| SCHEMBL27879166 | 0.91 | MDM2 (0.69) | MDM2MARS1KMOKDM4ELMNA | |
| SCHEMBL1437137 | 0.91 | MDM2 (0.87) | MDM2PIN1ATMPKMPTGER4 | |
| SCHEMBL1443425 | 0.90 | MDM2 (1.00) | MDM2PIN1ATMPKMPTGER4 | |
| SCHEMBL1436973 | 0.89 | MDM2 (0.89) | MDM2PIN1ATMPKMPTGER4 | |
| SCHEMBL9893927 | 0.89 | MDM2 (1.00) | MDM2PIN1ATMPKMPTGER4 | |
| SCHEMBL9893785 | 0.89 | MDM2 (0.72) | MDM2PIN1MARS1KMOGABRA2 | |
| SCHEMBL1437102 | 0.88 | MDM2 (0.64) | MDM2GABRA2GABRB2 | |
| SCHEMBL27879169 | 0.88 | MDM2 (0.69) | MDM2MARS1KMOCTSALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102574785-A | Tetra-substituted heteroaryl compounds and their use as MDM2 and/or MDM4 modulators | NOVARTIS AG | 2012-07-11 | — | — | CN | disclosed |
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | MDM2 2/4885PIN1 844/4885MARS1 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.